Researchers at Queen’s University Belfast (Queen’s) in the United Kingdom have developed a test that could radically improve the lives of people with oesophageal cancer through a personalised medicine approach.
The researchers at Queen’s and the University of Cambridge, UK, in partnership with the stratified medicine company Almac Diagnostic Services, have validated a test that, for the first time, could enable clinicians to decide the most appropriate chemotherapy for early stage oesophageal cancer.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
